ArticleDiscover oncology2026
Indigestible carbohydrates suppress colorectal cancer through IRF6/TRAF3/IFNα pathway.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systems-level analysis identifies IRF6 as an inhibitor of epithelial-mesenchymal transition.Journal of biological engineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is one of most common cancers with high morbidity and mortality. Previous studies have indicated that people with higher dietary fiber intake, including non-digestible starch (NDCs), have a lower risk of CRC. The exact mechanism of NDCs in reducing CRC risk and processes remains unclear. MATERIALS AND
methodsIRF6, TRAF3 and IFNα expressions were detected in CRC samples, with subsequent analysis of the correlations between IRF6 and TRAF3 and between IRF6 and IFNα. The effects of sodium butyrate (NaB) on IRF6, TRAF3 and IFNα expression in CRC, cell proliferation, migration and EMT were confirmed in vitro. The interaction between IRF6 and TRAF3 were verified by WB and immunoprecipitation experiments. The effects of NDCs on tumor growth and IRF6 expression were confirmed in vivo.
resultsOur results showed that IRF6, TRAF3, IFNα expression in CRC was significantly lower than that in adjacent tissues, and IRF6 expression correlated with TRAF3 and IFNα positively. NaB and IRF6 could significantly inhibit the cell proliferation, migration and EMT of CRC cells and IRF6 could bind to TRAF3. NDCs could reduce the lesions of in situ CRC induced by inflammation, and IRF6 expression in colon tissue of mice in NDCs group was significantly increased.
conclusionOur study suggested that NDCs intake may regulate IFNα activation by up-regulating IRF6 to inhibit TRAF3 degradation to inhibit the proliferation and migration of tumor cells. Our study will provide theoretical basis and data support for reducing the risk of CRC through dietary regulation and exploring potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.